Endotypes of allergic diseases and asthma: An important step in building blocks for the future of precision medicine

Allergology International

Volumn 65, Issue 3, 2016, Pages 243-252

  Agache, Ioana ^a   Akdis, Cezmi A ^b,c  

^a TRANSILVANIA UNIVERSITY OF BRASOV   (Romania)

^b UNIVERSITY OF ZURICH   (Switzerland)

^c CHRISTINE KÜHNE CENTER FOR ALLERGY RESEARCH AND EDUCATION CK CARE   (Switzerland)

Author keywords

Allergic diseases; Asthma; Biomarkers; Endotypes; Precision medicine

Indexed keywords

BIOLOGICAL MARKER; CXCL1 CHEMOKINE; EPITHELIAL DERIVED NEUTROPHIL ACTIVATING FACTOR 78; GAMMA INTERFERON; IMMUNOGLOBULIN E; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 13; INTERLEUKIN 17; INTERLEUKIN 17C; INTERLEUKIN 1BETA; INTERLEUKIN 22; INTERLEUKIN 25; INTERLEUKIN 31; INTERLEUKIN 33; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 8; INTERLEUKIN 9; MONOCYTE CHEMOTACTIC PROTEIN 1; THYMIC STROMAL LYMPHOPOIETIN; TUMOR NECROSIS FACTOR;

ADAPTIVE IMMUNITY; ALLERGIC ASTHMA; ALLERGIC DISEASE; ALLERGIC RHINITIS; ANTIBODY PRODUCTION; ASTHMA; ATOPIC DERMATITIS; CHRONIC RHINOSINUSITIS; CYTOKINE RELEASE; DNA METHYLATION; ENVIRONMENTAL EXPOSURE; EPIGENETICS; FOOD ALLERGY; HUMAN; IMMUNOPHENOTYPING; IMMUNOREGULATION; INNATE IMMUNITY; LUNG LAVAGE; MACROPHAGE ACTIVATION; METABOLISM; NERVOUS SYSTEM INFLAMMATION; NEUTROPHILIA; NONHUMAN; PATHOPHYSIOLOGY; PATIENT CARE; PERSONALIZED MEDICINE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PSYCHOLOGICAL ASPECT; REVIEW; TH17 CELL; TH2 CELL; ANIMAL; BIOLOGY; GENETIC EPIGENESIS; HYPERSENSITIVITY; IMMUNITY; IMMUNOLOGY; PROCEDURES; T LYMPHOCYTE SUBPOPULATION;

ANIMALS; ASTHMA; BIOMARKERS; COMPUTATIONAL BIOLOGY; EPIGENESIS, GENETIC; HUMANS; HYPERSENSITIVITY; IMMUNITY; PHENOTYPE; PRECISION MEDICINE; T-LYMPHOCYTE SUBSETS;

EID: 84973138132     PISSN: 13238930     EISSN: 14401592     Source Type: Journal    
DOI: 10.1016/j.alit.2016.04.011     Document Type: Review

References (121)

1. 1 Akdis, C.A., Ballas, Z., Precision medicine & precision health: building blocks to foster a revolutionary healthcare model. J Allergy Clin Immunol 137 (2016), 1359–1361.
2. 2 Galli, S., Toward precision medicine and health: promises opportunities and challenges in allergic diseases. J Allergy Clin Immunol 137 (2016), 1289–1300.
3. 3 Muraro, A., Lemanske, R.F., Hellings, P.W., Akdis, C.A., Bieber, T., Casale, T.B., et al. Precision medicine in patients with allergic diseases: airway diseases and atopic dermatitis—PRACTALL document of the European Academy of Allergy and Clinical Immunology and the American Academy of Allergy, Asthma & Immunology. J Allergy Clin Immunol 137 (2016), 1347–1358.
4. 4 Lötvall, J., Akdis, C.A., Bacharier, L.B., Bjermer, L., Casale, T.B., Custovic, A., et al. Asthma endotypes: a new approach to classification of disease entities within the asthma syndrome. J Allergy Clin Immunol 127 (2011), 355–360.
5. 5 Agache, I., Akdis, C., Jutel, M., Virchow, J.C., Untangling asthma phenotypes and endotypes. Allergy 67 (2012), 835–846.
6. 6 Agache, I., From phenotypes to endotypes to asthma treatment. Curr Opin Allergy Clin Immunol 13 (2013), 249–256.
7. 7 Agache, I., Sugita, K., Morita, H., Akdis, M., Akdis, C.A., The complex type 2 endotype in allergy and asthma: from laboratory to bedside. Curr Allergy Asthma Rep, 15, 2015, 29.
8. 8 DeVries, A., Vercelli, D., Early predictors of asthma and allergy in children: the role of epigenetics. Curr Opin Allergy Clin Immunol 15 (2015), 435–439.
9. 9 DeVries, A., Wlasiuk, G., Miller, S.J., Bosco, A., Stern, D.A., Nicodemus-Johnson, J., et al. Neonatal epigenetic predictors of childhood asthma map to immunoregulatory and pro-inflammatory pathways [abstract]. Am J Respir Crit Care Med, 191, 2015, A3524.
10. 10 Martino, D., Joo, J.E., Sexton-Oates, A., Dang, T., Allen, K., Saffery, R., et al. Epigenome wide association study reveals longitudinally stable DNA methylation differences in CD4þ T cells from children with IgE-mediated food allergy. Epigenetics 9 (2014), 998–1006.
11. 11 Lockett, G.A., Soto-Ramírez, N., Ray, M.A., Everson, T.M., Xu, C.J., Patil, V.K., et al. Association of season of birth with DNA methylation and allergic disease. Allergy, 2016, 10.1111/all.12882.
12. 12 Yang, I.V., Pedersen, B.S., Liu, A., O'Connor, G.T., Teach, S.J., Kattan, M., et al. DNA methylation and childhood asthma in the inner city. J Allergy Clin Immunol 136 (2015), 69–80.
13. 13 Murphy, T.M., Wong, C.C., Arseneault, L., Burrage, J., Macdonald, R., Hannon, E., et al. Methylomic markers of persistent childhood asthma: a longitudinal study of asthma-discordant monozygotic twins. Clin Epigenetics, 7, 2015, 130.
14. 14 Martino, D., Dang, T., Sexton-Oates, A., Prescott, S., Tang, M.L., Dharmage, S., et al. Blood DNA methylation biomarkers predict clinical reactivity in food-sensitized infants. J Allergy Clin Immunol 135 (2015), 1319–1328.
15. 15 Wagner, J.A., Overview of biomarkers and surrogate endpoints in drug development. Dis Markers 18 (2002), 41–46.
16. 16 Wagner, J.A., Williams, S.A., Webster, C.J., Biomarkers and surrogate end points for fit-for-purpose development and regulatory evaluation of new drugs. Clin Pharmacol Ther 81 (2007), 104–107.
17. 17 Berry, A., Busse, W.W., Biomarkers in asthma; has their time come to direct treatment?. J Allergy Clin Immunol 137 (2016), 1317–1324.
18. 18 Goodsaid, F.M., Frueh, F.W., Mattes, W., Strategic paths for biomarker qualification. Toxicology 245 (2008), 219–223.
19. 19 Muraro, A., Fokkens, W.J., Pietikainen, S., Borrelli, D., Agache, I., Bousquet, J., et al. European symposium on precision medicine in allergy and airways diseases: report of the European Union Parliament Symposium (October 14, 2015). Allergy, 2015, 10.1111/all.12819.
20. 20 Jameson, J.L., Longo, D.L., Precision medicine – personalized, problematic, and promising. N Engl J Med 372 (2015), 2229–2234.
21. 21 Agache, I., Strasser, D.L., Klenk, A., Agache, C., Farine, H., Ciobanu, C., et al. Serum IL-5 and IL-13 consistently serve as the best predictors for the blood eosinophilia phenotype in adult asthmatics. Allergy, 2016, 10.1111/all.12906.
22. 22 Howrylak, J.A., Moll, M., Weiss, S.T., Raby, B.A., Wu, W., Xing, E.P., Gene expression profiling of asthma phenotypes demonstrates molecular signatures of atopy and asthma control. J Allergy Clin Immunol, 2016, 10.1016/j.jaci.2015.09.058.
23. 23 Woodruff, P.G., Modrek, B., Choy, D.F., Jia, G., Abbas, A.R., Ellwanger, et al. T-helper type 2-driven inflammation defines major subphenotypes of asthma. Am J Respir Crit Care Med 180 (2009), 388–395.
24. 24 Meyer, N., Dallinga, J.W., Nuss, S.J., Moonen, E.J., van Berkel, J.J., Akdis, C., et al. Defining adult asthma endotypes by clinical features and patterns of volatile organic compounds in exhaled air. Respir Res, 15, 2014, 136.
25. 25 Meyer, N., Nuss, S.J., Rothe, T., Siebenhüner, A., Akdis, C.A., Menz, G., Differential serum protein markers and the clinical severity of asthma. J Asthma Allergy 7 (2014), 67–75.
26. 26 Peters, M.C., Mekonnen, Z.K., Yuan, S., Bhakta, N.R., Woodruff, P.G., Fahy, J.V., Measures of gene expression in sputum cells can identify TH2-high and TH2-low subtypes of asthma. J Allergy Clin Immunol 133 (2014), 388–394.
27. 27 Yan, X., Chu, J.H., Gomez, J., Koenigs, M., Holm, C., He, X., et al. Noninvasive analysis of the sputum transcriptome discriminates clinical phenotypes of asthma. Am J Respir Crit Care Med 191 (2015), 1116–1125.
28. 28 Williams-DeVane, C.R., Reif, D.M., Hubal, E.C., Bushel, P.R., Hudgens, E.E., Gallagher, J.E., et al. Decision tree-based method for integrating gene expression, demographic, and clinical data to determine disease endotypes. BMC Syst Biol, 7, 2013, 119.
29. 29 Hagenaars, J., McCutcheon, A., (eds.) Applied Latent Class Analysis, 2002, Cambridge University Press, Cambridge, 454.
30. 30 Pe'er, D., Bayesian network analysis of signaling networks: a primer. Sci STKE, 2005, 2005, pl4.
31. 31 Altaf-Ul-Amin, M., Katsuragi, T., Sato, T., Kanaya, S., A glimpse to background and characteristics of major molecular biological networks. Biomed Res Int, 2015, 2015, 540297.
32. 32 Mastalerz, L., Celejewska-Wójcik, N., Wójcik, K., Gielicz, A., Ćmiel, A., Ignacak, M., et al. Induced sputum supernatant bioactive lipid mediators can identify subtypes of asthma. Clin Exp Allergy 45 (2015), 1779–1789.
33. 33 Hinks, T., Zhou, X., Staples, K., Dimitrov, B., Manta, A., Petrossian, T., et al. Multidimensional endotypes of asthma: topological data analysis of cross-sectional clinical, pathological, and immunological data. Lancet, 385(Suppl. 1), 2015, S42.
34. 34 Hinks, T.S., Brown, T., Lau, L.C., Rupani, H., Barber, C., Elliott, S., et al. Multidimensional endotyping in patients with severe asthma reveals inflammatory heterogeneity in matrix metalloproteinases and chitinase 3-like protein 1. J Allergy Clin Immunol, 2016, 10.1016/j.jaci.2015.11.020.
35. 35 Friedman, J.H., Multivariate adaptive regression splines. Ann Stat 19 (1991), 1–67.
36. 36 Brasier, A.R., Victor, S., Ju, H., Busse, W.W., Curran-Everett, D., Bleecker, E., et al. Predicting intermediate phenotypes in asthma using bronchoalveolar lavage-derived cytokines. Clin Transl Sci 3 (2010), 147–157.
37. 37 George, B.J., Reif, D.M., Gallagher, J.E., Williams-DeVane, C.R., Heidenfelder, B.L., Hudgens, E.E., et al. Data-driven asthma endotypes defined from blood biomarker and gene expression data. PLoS One, 10, 2015, e0117445.
38. 38 McGeachie, M.J., Dahlin, A., Qiu, W., Croteau-Chonka, D.C., Savage, J., Wu, A.C., et al. The metabolomics of asthma control: a promising link between genetics and disease. Immun Inflamm Dis 3 (2015), 224–238.
39. 39 Yang, F., Yu, X., Wang, L., Liu, L., Xu, X., Zheng, X., et al. Identify asthma genes across three phases based on protein-protein interaction network. IET Syst Biol 9 (2015), 135–140.
40. 40 Greiner, A.N., Hellings, P.W., Rotiroti, G., Scadding, G.K., Allergic rhinitis. Lancet 378 (2011), 2112–2122.
41. 41 Akdis CA. The underlying mechanisms in allergy (overview). EAACI Global Atlas of Allergy. http://www.eaaci.org/resources/scientific-output/global-atlas-of-allergy.html.
42. 42 Dougherty, R.H., Sidhu, S.S., Raman, K., Solon, M., Solberg, O.D., Caughey, G.H., et al. Accumulation of intraepithelial mast cells with a unique protease phenotype in T(H)2-high asthma. J Allergy Clin Immunol 125 (2010), 1046–1053.
43. 43 Irvin, C., Zafar, I., Good, J., Rollins, D., Christianson, C., Gorska, M.M., et al. Increased frequency of dual-positive TH2/TH17 cells in bronchoalveolar lavage fluid characterizes a population of patients with severe asthma. J Allergy Clin Immunol 134 (2014), 1175–1186.
44. 44 Steinke, J.W., Liu, L., Huyett, P., Negri, J., Payne, S.C., Borish, L., Prominent role of IFN-γ in patients with aspirin-exacerbated respiratory disease. J Allergy Clin Immunol 132 (2013), 856–865 e1-3.
45. 45 Marijsse, G.S., Seys, S.F., Schelpe, A.-S., Dilissen, E., Goeminne, P., Dupont, L.J., et al. Obese individuals with asthma preferentially have a high IL-5/IL-17A/IL-25 sputum inflammatory pattern. Am J Respir Crit Care Med 189 (2014), 1284–1285.
46. 46 Hammad, H., Lambrecht, B.N., Barrier epithelial cells and the control of type 2 immunity. Immunity 43 (2015), 29–40.
47. 47 Green, R.H., Brightling, C.E., Woltmann, G., Parker, D., Wardlaw, A.J., Pavord, I.D., Analysis of induced sputum in adults with asthma: identification of subgroup with isolated sputum neutrophilia and poor response to inhaled corticosteroids. Thorax 57 (2002), 875–879.
48. 48 Haldar, P., Brightling, C.E., Hargadon, B., Gupta, S., Monteiro, W., Sousa, A., et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med 360 (2009), 973–984.
49. 49 Nair, P., Pizzichini, M.M., Kjarsgaard, M., Inman, M.D., Efthimiadis, A., Pizzichini, E., et al. Mepolizumab for prednisone-dependent asthma with sputum eosinophilia. N Engl J Med 360 (2009), 985–993.
50. 50 Corren, J., Lemanske, R.F., Hanania, N.A., Korenblat, P.E., Parsey, M.V., Arron, J.R., et al. Lebrikizumab treatment in adults with asthma. N Engl J Med 365 (2011), 1088–1098.
51. 51 Hanania, N.A., Noonan, M., Corren, J., Korenblat, P., Zheng, Y., Fischer, S.K., et al. Lebrikizumab in moderate-to-severe asthma: pooled data from two randomised placebo-controlled studies. Thorax 70 (2015), 748–756.
52. 52 Wenzel, S., Ford, L., Pearlman, D., Spector, S., Sher, L., Skobieranda, F., et al. Dupilumab in persistent asthma with elevated eosinophil levels. N Engl J Med 368 (2013), 2455–2466.
53. 53 Pavord, I.D., Korn, S., Howarth, P., Bleecker, E.R., Buhl, R., Keene, O.N., et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet 380 (2012), 651–659.
54. 54 Ortega, H.G., Liu, M.C., Pavord, I.D., Brusselle, G.G., FitzGerald, J.M., Chetta, A., et al., MENSA Investigators. Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med 371 (2014), 1198–1207.
55. 55 Corren, J., Weinstein, S., Janka, L., Zangrilli, J., Garin, M., Phase 3 study of reslizumab in patients with poorly controlled asthma: effects across a broad range of eosinophil counts. Chest, 2016, 10.1016/j.chest.2016.03.018.
56. 56 Hanania, N.A., Wenzel, S., Rosén, K., Hsieh, H.J., Mosesova, S., Choy, D.F., et al. Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study. Am J Respir Crit Care Med 187 (2013), 804–811.
57. 57 Humbert, M., Busse, W., Hanania, N.A., Lowe, P.J., Canvin, J., Erpenbeck, V.J., et al. Omalizumab in asthma: an update on recent developments. J Allergy Clin Immunol Pract 2 (2014), 525–536.
58. 58 Hall, I.P., Fowler, A.V., Gupta, A., Tetzlaff, K., Nivens, M.C., Sarno, M., et al. Efficacy of BI 671800, an oral CRTH2 antagonist, in poorly controlled asthma as sole controller and in the presence of inhaled corticosteroid treatment. Pulm Pharmacol Ther 32 (2015), 37–44.
59. 59 Diamant, Z., Sidharta, P.N., Singh, D., O'Connor, B.J., Zuiker, R., Leaker, B.R., et al. Setipiprant, a selective CRTH2 antagonist, reduces allergen-induced airway responses in allergic asthmatics. Clin Exp Allergy 44 (2014), 1044–1052.
60. 60 Pettipher, R., Hunter, M.G., Perkins, C.M., Collins, L.P., Lewis, T., Baillet, M., et al. Heightened response of eosinophilic asthmatic patients to the CRTH2 antagonist OC000459. Allergy 69 (2014), 1223–1232.
61. 61 Akdis, C.A., Bachert, C., Cingi, C., Dykewicz, M.S., Hellings, P.W., Naclerio, R.M., et al. Endotypes and phenotypes of chronic rhinosinusitis: a PRACTALL document of the European Academy of Allergy and Clinical Immunology and the American Academy of Allergy, Asthma & Immunology. J Allergy Clin Immunol 131 (2013), 1479–1490.
62. 62 Barham, H.P., Osborn, J.L., Snidvongs, K., Mrad, N., Sacks, R., Harvey, R.J., Remodeling changes of the upper airway with chronic rhinosinusitis. Int Forum Allergy Rhinol 5 (2015), 565–572.
63. 63 Tomassen, P., Vandeplas, G., Van Zele, T., Cardell, L.O., Arebro, J., Olze, H., et al. Inflammatory endotypes of chronic rhinosinusitis based on cluster analysis of biomarkers. J Allergy Clin Immunol, 2016, 10.1016/j.jaci.2015.12.1324.
64. 64 Gevaert, P., Van Bruaene, N., Cattaert, T., Van Steen, K., Van Zele, T., Acke, F., et al. Mepolizumab, a humanized anti–IL-5 mAb, as a treatment option for severe nasal polyposis. J Allergy Clin Immunol 128 (2011), 989–995.
65. 65 Gevaert, P., Calus, L., Van Zele, T., Blomme, K., De Ruyck, N., Bauters, W., et al. Omalizumab is effective in allergic and nonallergic patients with nasal polyps and asthma. J Allergy Clin Immunol 131 (2013), 110–116.
66. 66 Bachert, C., Mannent, L., Naclerio, R.M., Mullol, J., Ferguson, B.J., Gevaert, P., et al. Effect of subcutaneous dupilumab on nasal polyp burden in patients with chronic sinusitis and nasal polyposis: a randomized clinical trial. JAMA 315 (2016), 469–479.
67. 67 Noda, S., Suárez-Fariñas, M., Ungar, B., Kim, S.J., de Guzman Strong, C., Xu, H., et al. The Asian atopic dermatitis phenotype combines features of atopic dermatitis and psoriasis with increased TH17 polarization. J Allergy Clin Immunol 136 (2015), 1254–1264.
68. 68 Czarnowicki, T., Gonzalez, J., Shemer, A., Malajian, D., Xu, H., Zheng, X., et al. Severe atopic dermatitis is characterized by selective expansion of circulating TH2/TC2 and TH22/TC22, but not TH17/TC17, cells within the skin-homing T-cell population. J Allergy Clin Immunol 136 (2015), 104–115.
69. 69 Czarnowicki, T., Esaki, H., Gonzalez, J., Malajian, D., Shemer, A., Noda, S., et al. Early pediatric atopic dermatitis shows only a cutaneous lymphocyte antigen (CLA)(+) TH2/TH1 cell imbalance, whereas adults acquire CLA(+) TH22/TC22 cell subsets. J Allergy Clin Immunol 136 (2015), 941–951.
70. 70 Beck, L.A., Thaçi, D., Hamilton, J.D., Graham, N.M., Bieber, T., Rocklin, R., et al. Dupilumab treatment in adults with moderate-to-severe atopic dermatitis. N Engl J Med 371 (2014), 130–139.
71. 71 Thaçi, D., Simpson, E.L., Beck, L.A., Bieber, T., Blauvelt, A., Papp, K., et al. Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial. Lancet 387 (2016), 40–52.
72. 72 Hamilton, J.D., Suárez-Fariñas, M., Dhingra, N., Cardinale, I., Li, X., Kostic, A., et al. Dupilumab improves the molecular signature in skin of patients with moderate-to-severe atopic dermatitis. J Allergy Clin Immunol 134 (2014), 1293–1300.
73. 73 Hotze, M., Baurecht, H., Rodríguez, E., Chapman-Rothe, N., Ollert, M., Fölster-Holst, R., et al. Increased efficacy of omalizumab in atopic dermatitis patients with wild-type filaggrin status and higher serum levels of phosphatidylcholines. Allergy 69 (2014), 132–135.
74. 74 Moore, W.C., Meyers, D.A., Wenzel, S.E., Teague, W.G., Li, H., Li, X., et al., National Heart, Lung, and Blood Institute's Severe Asthma Research Program. Identification of asthma phenotypes using cluster analysis in the Severe Asthma Research Program. Am J Respir Crit Care Med 181 (2010), 315–323.
75. 75 Baines, K.J., Simpson, J.L., Wood, L.G., Scott, R.J., Gibson, P.G., Transcriptional phenotypes of asthma defined by gene expression profiling of induced sputum samples. J Allergy Clin Immunol 127 (2011), 153–160.
76. 76 Lou, H., Meng, Y., Piao, Y., Zhang, N., Bachert, C., Wang, C., et al. Cellular phenotyping of chronic rhinosinusitis with nasal polyps. Rhinology, 2016 Jan 9 [Epub ahead of print].
77. 77 Zhang, N., Van Zele, T., Perez-Novo, C., Van Bruaene, N., Holtappels, G., DeRuyck, N., et al. Different types of T-effector cells orchestrate mucosal inflammation in chronic sinus disease. J Allergy Clin Immunol 122 (2008), 961–968.
78. 78 Kim, D.W., Kim, D.K., Jo, A., Jin, H.R., Eun, K.M., Mo, J.H., et al. Age-related decline of neutrophilic inflammation is associated with better postoperative prognosis in non-eosinophilic nasal polyps. PLoS One, 11, 2016, e0148442.
79. 79 Agache, I., Non-eosinophilic asthma endotypes. Curr Treat Options Allergy 2 (2015), 257–267.
80. 80 Simpson, J.L., Grissell, T.V., Douwes, J., Scott, R.J., Boyle, M.J., Gibson, P.G., Innate immune activation in neutrophilic asthma and bronchiectasis. Thorax 62 (2007), 211–218.
81. 81 Baines, K.J., Simpson, J.L., Wood, L.G., Scott, R.J., Fibbens, N.L., Powell, H., et al. Sputum gene expression signature of 6 biomarkers discriminates asthma inflammatory phenotypes. J Allergy Clin Immunol 133 (2014), 997–1007.
82. 82 Dejager, L., Dendoncker, K., Eggermont, M., Souffriau, J., Van Hauwermeiren, F., Willart, M., et al. Neutralizing TNFα restores glucocorticoid sensitivity in a mouse model of neutrophilic airway inflammation. Mucosal Immunol 8 (2015), 1212–1225.
83. 83 Mikami, Y., Matsuzaki, H., Horie, M., Noguchi, S., Jo, T., Narumoto, O., et al. Lymphotoxin β receptor signaling induces IL-8 production in human bronchial epithelial cells. PLoS One, 9, 2014, e114791.
84. 84 Baines, K.J., Simpson, J.L., Bowden, N.A., Scott, R.J., Gibson, P.G., Differential gene expression and cytokine production from neutrophils in asthma phenotypes. Eur Respir J 35 (2010), 522–531.
85. 85 Gao, P., Gibson, P.G., Baines, K.J., Yang, I.A., Upham, J.W., Reynolds, P.N., et al. Anti-inflammatory deficiencies in neutrophilic asthma: reduced galectin-3 and IL-1RA/IL-1ß. Respir Res, 16, 2015, 5.
86. 86 Simpson, J.L., Gibson, P.G., Yang, I.A., Upham, J., James, A., Reynolds, P.N., et al. Impaired macrophage phagocytosis in non-eosinophilic asthma. Clin Exp Allergy 43 (2013), 29–35.
87. 87 Marcinkiewicz, J., Stręk, P., Strus, M., Głowacki, R., Ciszek-Lenda, M., Zagórska-Świeży, K., et al. Staphylococcus epidermidis and biofilm-associated neutrophils in chronic rhinosinusitis. A pilot study. Int J Exp Pathol 96 (2015), 378–386.
88. 88 Simpson, J.L., Scott, R.J., Boyle, M.J., Gibson, P.G., Differential proteolytic enzyme activity in eosinophilic and neutrophilic asthma. Am J Resp Crit Care Med 172 (2005), 559–565.
89. 89 Russell, D.W., Wells, J.M., Blalock, J.E., Disease phenotyping in chronic obstructive pulmonary disease: the neutrophilic endotype. Curr Opin Pulm Med 22 (2016), 91–99.
90. 90 Nembrini, C., Marsland, B.J., Kopf, M., IL-17-producing T cells in lung immunity and inflammation. J Allergy Clin Immunol 123 (2009), 986–994.
91. 91 Yu, S., Kim, H.Y., Chang, Y.-J., DeKruyff, R.H., Umetsu, D.T., Innate lymphoid cells and asthma. J Allergy Clin Immunol 133 (2014), 943–950.
92. 92 Kim, H.Y., Lee, H.J., Chang, Y.-J., Pichavant, M., Shore, S.A., Fitzgerald, K.A., et al. Interleukin-17-producing innate lymphoid cells and the NLRP3 inflammasome facilitate obesity-associated airway hyperreactivity. Nat Med 20 (2014), 54–61.
93. 93 Mease, P.J., Inhibition of interleukin-17, interleukin-23 and the TH17 cell pathway in the treatment of psoriatic arthritis and psoriasis. Curr Opin Rheumatol 27 (2015), 127–133.
94. 94 Wilson, R.H., Whitehead, G.S., Nakano, H., Free, M.E., Kolls, J.K., Cook, D.N., Allergic sensitization through the airway primes Th17-dependent neutrophilia and airway hyperresponsiveness. Am J Respir Crit Care Med 180 (2009), 720–730.
95. 95 Zhao, J., Lloyd, C.M., Noble, A., Th17 responses in chronic allergic airway inflammation abrogate regulatory T-cell-mediated tolerance an contribute to airway remodeling. Mucosal Immunol 6 (2013), 335–346.
96. 96 Busse, W.W., Holgate, S., Kerwin, E., Chon, Y., Feng, J., Lin, J., et al. Randomized, double-blind, placebo-controlled study of brodalumab, a human anti-IL-17 receptor monoclonal antibody, in moderate to severe asthma. Am J Respir Crit Care Med 188 (2013), 1294–1302.
97. 97 Bullens, D.M., Truyen, E., Coteur, L., Dilissen, E., Hellings, P.W., Dupont, L.J., et al. IL-17 mRNA in sputum of asthmatic patients: linking T cell driven inflammation and granulocytic influx?. Respir Res, 7, 2006, 135.
98. 98 Agache, I., Ciobanu, C., Agache, C., Anghel, M., Increased serum IL-17 is an independent risk factor for severe asthma. Respir Med 104 (2010), 1131–1137.
99. 99 Molet, S., Hamid, Q., Davoine, F., Nutku, E., Taha, R., Pagé, N., et al. IL-17 is increased in asthmatic airways and induces human bronchial fibroblasts to produce cytokines. J Allergy Clin Immunol 108 (2001), 430–438.
100. 100 Barczyk, A., Pierzchala, W., Sozañska, E., Interleukin-17 in sputum correlates with airway hyperresponsiveness to methacholine. Respir Med 97 (2003), 726–733.
101. 101 Chien, J.W., Lin, C.Y., Yang, K.D., Lin, C.H., Kao, J.K., Tsai, Y.G., Increased IL-17A secreting CD41 T cells, serum IL-17 levels and exhaled nitric oxide are correlated with childhood asthma severity. Clin Exp Allergy 43 (2013), 1018–1026.
102. 102 Raedler, D., Ballenberger, N., Klucker, E., Böck, A., Otto, R., Prazeres da Costa, O., et al. Identification of novel immune phenotypes for allergic and non-allergic childhood asthma. J Allergy Clin Immunol 135 (2015), 81–91.
103. 103 Banuelos, J., Shin, S., Cao, Y., Bochner, B.S., Morales-Nebreda, L., Budinger, G.R., et al. BCL-2 protects human and mouse Th17 cells from glucocorticoid-induced apoptosis. Allergy, 2016, 10.1111/all.12840.
104. 104 Gupta, A., Dimeloe, S., Richards, D.F., Chambers, E.S., Black, C., Urry, Z., et al. Defective IL-10 expression and in vitro steroid-induced IL-17A in paediatric severe therapy-resistant asthma. Thorax 69 (2014), 508–515.
105. 105 Chambers, E.S., Nanzer, A.M., Pfeffer, P.E., Richards, D.F., Timms, P.M., Martineau, A.R., et al. Distinct endotypes of steroid-resistant asthma characterized by IL-17A(high) and IFN-γ(high) immunophenotypes: potential benefits of calcitriol. J Allergy Clin Immunol 136 (2015), 628–637.
106. 106 Olcott, C.M., Han, J.K., Cunningham, T.D., Franzese, C.B., Interleukin-9 and interleukin-17C in chronic rhinosinusitis. Int Forum Allergy Rhinol, 2016, 10.1002/alr.21745.
107. 107 Ramezanpour, M., Moraitis, S., Smith, J.L., Wormald, P.J., Vreugde, S., Th17 cytokines disrupt the airway mucosal barrier in chronic rhinosinusitis. Mediators Inflamm, 2016, 2016, 9798206.
108. 108 Shin, H.W., Kim, D.K., Park, M.H., Eun, K.M., Lee, M., So, D., et al. IL-25 as a novel therapeutic target in nasal polyps of patients with chronic rhinosinusitis. J Allergy Clin Immunol 135 (2015), 1476–1485.
109. 109 Ma, L., Xue, H.B., Guan, X.H., Shu, C.M., Wang, F., Zhang, J.H., et al. The imbalance of Th17 cells and CD4(+) CD25(high) Foxp3(+) Treg cells in patients with atopic dermatitis. J Eur Acad Dermatol Venereol 2 (2014), 1079–1086.
110. 110 Bonefeld, C.M., Petersen, T.H., Bandier, J., Agerbeck, C., Linneberg, A., Ross-Hansen, K., et al. Epidermal filaggrin deficiency mediates increased systemic Th17 immune response. Br J Dermatol, 2016, 10.1111/bjd.14570.
111. 111 Van Gerven, L., Alpizar, Y.A., Wouters, M.M., Hox, V., Hauben, E., Jorissen, M., et al. Capsaicin treatment reduces nasal hyperreactivity and transient receptor potential cation channel subfamily V, receptor 1 (TRPV1) overexpression in patients with idiopathic rhinitis. J Allergy Clin Immunol 133 (2014), 1332–1339.
112. 112 Yamaguchi, J., Aihara, M., Kobayashi, Y., Kambara, T., Ikezawa, Z., Quantitative analysis of nerve growth factor (NGF) in the atopic dermatitis and psoriasis horny layer and effect of treatment on NGF in atopic dermatitis. J Dermatol Sci 53 (2009), 48–54.
113. 113 Peters, E.M., Michenko, A., Kupfer, J., Kummer, W., Wiegand, S., Niemeier, V., et al. Mental stress in atopic dermatitis–neuronal plasticity and the cholinergic system are affected in atopic dermatitis and in response to acute experimental mental stress in a randomized controlled pilot study. PLoS One, 9, 2014, e113552.
114. 114 Cosmi, L., Maggi, L., Santarlasci, V., Capone, M., Cardilicchia, E., Frosali, F., et al. Identification of a novel subset of human circulating memory CD4(+) T cells that produce both IL-17A and IL-4. J Allergy Clin Immunol 125 (2010), 222–230.
115. 115 Lam, E.P., Kariyawasam, H.H., Rana, B.M., Durham, S.R., McKenzie, A.N., Powell, N., et al. IL-25/IL-33-responsive TH2 cells characterize nasal polyps with a default TH17 signature in nasal mucosa. J Allergy Clin Immunol, 2015, 10.1016/j.jaci.2015.10.019.
116. 116 Nakajima, S., Kitoh, A., Egawa, G., Natsuaki, Y., Nakamizo, S., Moniaga, C.S., et al. IL-17A as an inducer for Th2 immune responses in murine atopic dermatitis models. J Invest Dermatol 134 (2014), 2122–2130.
117. 117 Ponichtera, H.E., Shainheit, M.G., Liu, B.C., Raychowdhury, R., Larkin, B.M., Russo, J.M., et al. CD209a expression on dendritic cells is critical for the development of pathogenic Th17 cell responses in murine schistosomiasis. J Immunol 192 (2014), 4655–4665.
118. 118 Choy, D.F., Hart, K.M., Borthwick, L.A., Shikotra, A., Nagarkar, D.R., Siddiqui, S., et al. TH2 and TH17 inflammatory pathways are reciprocally regulated in asthma. Sci Transl Med, 7, 2015 301ra129.
119. 119 Sutherland, T.E., Logan, N., Rückerl, D., Humbles, A.A., Allan, S.M., Papayannopoulos, V., et al. Chitinase-like proteins promote IL-17-mediated neutrophilia in a tradeoff between nematode killing and host damage. Nat Immunol 15 (2014), 1116–1125.
120. 120 Chen, F., Wu, W., Millman, A., Craft, J.F., Chen, E., Patel, N., et al. Neutrophils prime a long-lived effector macrophage phenotype that mediates accelerated helminth expulsion. Nat Immunol 15 (2014), 938–946.
121. 121 Mizutani, N., Nabe, T., Yoshino, S., IL-17A promotes the exacerbation of IL-33-induced airway hyperresponsiveness by enhancing neutrophilic inflammation via CXCR2 signaling in mice. J Immunol 192 (2014), 1372–1384.